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AKT inhibition is associated with chemosensitisation in the
pancreatic cancer cell line MIA-PaCa-2
BN Fahy1, M Schlieman1, S Virudachalam1 and RJ Bold*,1
1Department of Surgical Oncology, University of California Davis Cancer Center, Sacramento, CA, USA
Activation of the serine/threonine kinase AKT is common in pancreatic cancer; inhibition of which sensitises cells to the apoptotic
effect of chemotherapy. Of the various downstream targets of AKT, we examined activation of the NF-kB transcription factor and
subsequent transcriptional regulation of BCL-2 gene family in pancreatic cancer cells. Inhibition of either phosphatidylinositol-3 kinase
or AKT led to a decreased protein level of the antiapoptotic gene BCL-2 and an increased protein level of the proapoptotic gene
BAX. Furthermore, inhibition of AKT decreased the function of NF-kB, which is capable of transcriptional regulation of the BCL-2
gene. Inhibiting this pathway had little effect on the basal level of apoptosis in pancreatic cancer cells, but increased the apoptotic
effect of chemotherapy. The antiapoptotic effect of AKT activation in pancreatic cancer cells may involve transcriptional induction of a
profile of BCL-2 proteins that confer resistance to apoptosis; alteration of this balance allows sensitisation to the apoptotic effect of
chemotherapy.
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Pancreatic cancer is a highly lethal malignancy resistant to the
apoptosis-inducing effects of radio- and chemotherapy (Heine-
mann, 2002). Recent reports have demonstrated that the phos-
phatidylinositol-3 kinase (PI3K)/AKT pathway is a potent survival
signal that may mediate resistance to the apoptotic effects of
chemotherapy and radiation therapy in a variety of cancer types
(Kandel and Hay, 1999; Brazil and Hemmings, 2001; Cantrell,
2001). Recent reports have suggested that AKT, a target of PI3K, is
phosphorylated and thus activated under basal conditions in a
variety of pancreatic cancer cell lines (Xue et al, 2000; Bondar et al,
2002; Samatar et al, 2002). The mechanism of AKT activation in
pancreatic cancer remains unknown, although the majority of cell
lines examined to date harbour constitutively activated AKT.
Inhibition of PI3K, the upstream activator of AKT, has been shown
to sensitise various pancreatic cancer cell lines to the apoptotic
effect of chemotherapy in vitro (Ng et al, 2000; Perugini et al, 2000;
Yao et al, 2002). Furthermore, using these cell lines in animal
studies, inhibition of PI3K was well tolerated and increased the
efficacy of chemotherapy in vivo (Ng et al, 2000; Bondar et al,
2002).
The downstream targets of AKT include regulators of apoptosis
(BAD, caspase-9), glucose metabolism (glycogen kinase), various
transcription factors (CREB and the forkhead family of transcrip-
tion factors), and finally the I-kappaB kinases (IKKs). It remains
unclear, however, which of these targets is involved in the
antiapoptotic effect of AKT activation. The NF-kB transcription
factor appears to be involved in the apoptotic resistance of
pancreatic cancer. This is based on observations of constitutive
activation of NF-kB in pancreatic cancer cells (Wang W et al,
1999) as well as the fact that inhibition of NF-kB decreases cell
survival (Shah et al, 2001) and enhances the apoptotic effect of
chemotherapy in pancreatic cancer cells (Arlt et al, 2001).
NF-kB transcription factors can regulate the expression of
over 100 different genes dependent on the various functional
forms of NF-kB, the stimulus of NF-kB activation and cell type
examined. NF-kB has been shown to regulate transcriptionally
the expression of several members of the BCL-2 gene family,
including BCL-XL (Chen et al, 2000) and A1 (Wang CY et al, 1999).
BCL-2 remains the prototypic antiapoptotic protein and the data
are less clear as to whether NF-kB regulates its transcription. There
are reports of activation or inhibition as well as reports
demonstrating no NF-kB-dependent transcriptional effect in the
BCL-2 promoter (Sohur et al, 1999; Catz and Johnson, 2001;
Potoka et al, 2002). In pancreatic cancer, BCL-2 is frequently
overexpressed and its overexpression confers chemo- and radio-
resistance and enhances tumorigenic and metastatic capability
(Bold et al, 1999a, b; Nio et al, 2001; Su et al, 2001). However,
it remains uncertain as to whether AKT or NF-kB is involved in
the mechanism of BCL-2 transcriptional activation in pancreatic
cancer.
Therefore, given the preliminary cellular studies that demon-
strate that the inhibition of PI3K/AKT sensitises pancreatic cancer
to the apoptotic effect of chemotherapy, we sought to determine
the molecular events that may mediate this effect. The current
study examines the hypothesis that a survival signal from AKT
activation is mediated by NF-kB and subsequent transcriptional
regulation of BCL-2 gene family members; furthermore, inhibition
of this pathway sensitises pancreatic cancer cells to the apoptotic
effect of gemcitabine.
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MATERIALS AND EXPERIMENTAL PROCEDURES
Materials
All chemical reagents were purchased from Sigma Chemical
Company (St Louis, MO, USA) unless otherwise specified.
LY294002 was obtained from New England BioLabs (Beverly,
MA, USA) and is a well-established inhibitor of PI3K-mediated
activation of AKT (Cuenda and Alessi, 2000). Cell culture supplies
and media were purchased from Becton Dickinson (San Diego, CA,
USA) and Gibco/BRL Life Technologies (Gaithersburg, MD, USA),
respectively. Plasmids for transfection experiments were purified
using Qiagen’s maxi kit (Valencia, CA, USA). The antibodies used
included monoclonal antibodies to BCL-2, BAX, BAK, BCL-XL and
MCL-1 (BD Pharmingen, San Diego, CA, USA), a polyclonal anti-
body to phospho-AKT (serine-473) (Biosource International Inc.,
Camarillo, CA, USA), polyclonal antibody to AKT (Cell Signalling
Technology, Inc., Beverly, MA, USA), a polyclonal antibody to
actin (Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA) and a
monoclonal antibody to the p50 subunit of NF-kB (Oncogene
Research Products, Boston, MA, USA). The luciferase assay kit was
purchased from Promega Corp. (Madison, WI, USA). The
dominant-negative PI3K and AKT constructs were kindly provided
by Dr Hsing-Jien Kung (UC Davis). These constructs have been
developed to inhibit specifically the enzymatic activity of PI3K and
AKT and are used as molecular inhibitors of these signalling
cascade intermediaries (Aoki et al, 1998; Osada et al, 1999).
Cell culture
The human pancreatic adenocarcinoma cell lines MIA-PaCa-2 and
PANC-1 were obtained from the American Type Culture Collection
(Rockville, MD, USA). The MIA-PaCa-2 cell line has been
previously demonstrated to harbour constitutively activated AKT
(Samatar et al, 2002). Cells were cultured in Dulbecco’s modified
Eagle’s medium supplemented with 10% fetal calf serum, sodium
pyruvate, nonessential amino acids, L-glutamine and penicillin/
streptomycin antibiotics. The cells were maintained in a humidi-
fied incubator containing 10% CO2 at 371C. The cells underwent
serum starvation for the 24 h prior to treatment with LY294002 or
transient transfection.
Western blotting
Following various treatments, cells were harvested by trypsinisa-
tion (trypsin 0.25% w v1, 1 mM ethylenediaminetetraacetic acid).
The cells were lysed in a lysis buffer containing 150 mM NaCl, 1%
Triton X-100 and 25 mM Tris (pH 7.5). Debris was sedimented by
centrifugation for 5 min at 12 000 g, and the supernatants were
solubilised for 5 min at 1001C in Laemmli’s sodium dodecyl
sulphate–polyacrylamide gel electrophoresis (SDS –PAGE) sample
buffer containing 100 mM dithiothreitol. Protein concentrations of
the lysates were determined with a protein quantitation kit (Bio-
Rad Laboratories, Hercules, CA, USA), and 50 mg of each sample
was separated on a 10% SDS–PAGE gel. Separated polypeptides
were then electrophoretically transferred to 0.2-mm nitrocellulose
membranes (Schleicher & Schuell, Keene, NH, USA). Membranes
were blocked for 1 h in a Tris-buffered saline-Tween (25 mM Tris,
pH 8.0, 150 mM NaCl, and 0.05% Tween-20) containing 5% (w v1)
nonfat dried milk. The blots were then probed overnight with
primary antibodies and developed using species-specific secondary
and tertiary antisera. Immunoreactive material was detected by the
enhanced chemiluminescence technique (Amersham).
BCL-2 and NF-jB promoter activity
Transcriptional regulation of the BCL-2 gene was determined using
a BCL-2 promoter/luciferase construct. A 3.7 kb fragment of the 50
untranslated region just upstream of the ATG initiation codon of
BCL-2 (Miyashita et al, 1994) was generously provided by Dr
Toshiyuki Miyashita (National Children’s Medical Research
Center, Tokyo, Japan). This fragment of the BCL-2 promoter was
cloned into the pGL3-basic luciferase reporter plasmid (Promega
Corp.). The NF-kB luciferase plasmid contains four tandem copies
of the NF-kB consensus sequence fused to a TATA-like promoter
(Clontech, Palo Alto, CA, USA). BCL-2 promoter activity was
normalised to the activity of the control Renilla luciferase reporter,
pRL-TK (Promega Corp.). Following 6 h of pretreatment with the
various inhibitors, the promoter/luciferase reporter plasmids,
BCL-2 or NF-kB (2.5mg), plus the control promoter/reporter,
pRL-TK (0.25 mg) were transiently transfected in MIA-PaCa-2 cells
using lipofectin reagent (Life Technologies, Inc.). Fresh medium
was applied after the cells had been in the transfection reagent for
8–12 h. The cells were harvested 24–48 h after transfection by
gentle scraping and resuspended in luciferase lysis buffer.
Dual luciferase assays were performed according to the
manufacturer’s protocol (Promega Corp.). A volume of 20 ml of
sample supernatant was mixed with 100 ml Luciferase Assay
Reagent II followed by a 10 s reading of firefly luciferase activity
using an Analytical Luminescence Laboratory Luminometer
(Monolight 2010) followed by the addition of 100 ml of Stop and
Glo reagentt (Promega Corp.). Dual luciferase assays were
expressed as the ratio of firefly/Renilla RLUs. All experiments
were performed in triplicate and repeated on at least three
separate occasions; representative data from a single experiment
are shown.
Site-directed mutagenesis of putative NF-kB sites within the BCL-2
promoter Putative NF-kB sites within the BCL-2 promoter were
identified using transcriptional element site software (Schug
and Overton, 1997). A site that is homologous to the NF-kB
consensus sequence (50GGGTNNYYCC30) was altered by site-
directed mutagenesis using a commercially available kit (Promega
Corp.). A mutagenic oligonucleotide was synthesised to mutate
two bases in the putative NF-kB sequence at 736 nt (wild type:
50GGGATTCCTGC30; mutant: 50GTTATTCCTGC30). It has been
recently shown that mutation of the second guanine base in an NF-
kB binding site essentially eliminates both p50/p50 and p50/p65
NF-kB binding (Udalova et al, 2002). DNA sequencing was used to
confirm the site-directed mutagenesis.
Electrophoretic mobility shift assay Cell extracts were prepared
using a commercially available nuclear extraction kit according to
the manufacturer’s protocol (Pierce, Rockford, IL, USA). Electro-
phoretic mobility shift assay (EMSA) was performed according to
the provided protocol (Promega Corp.). In brief, a 21-mer
oligonucleotide corresponding to a putative NF-kB site in the
BCL-2 promoter was radiolabelled with [g-32P]ATP by a T4 kinase
reaction. Nucleotides were purified by chromatography through a
G-25 spin column (Roche Diagnostics Corp., Indianapolis, IN,
USA) equilibrated in TE buffer. In all, 10 mg of nuclear protein
extract were incubated with the radiolabelled NF-kB oligonucleo-
tide for 20 min at room temperature. Supershift experiments were
performed by incubating the radiolabelled NF-kB oligonucleotide
with 1 ml of p50 antibody for 1 h on ice prior to incubation with the
nuclear protein extracts. DNA : protein complexes were separated
by electrophoresis through a nondenaturing 4% polyacrylamide
gel in 0.5 TBE at 100 V for 2.5 h. Autoradiographic films were
developed following 18 h exposure to the gels (201C).
Determination of apoptotic cells by FACS analysis Cell cycle
analysis and quantification of apoptosis analysis was carried out
as described previously using propidium iodide (PI) staining
and fluorescence-activated cell sorting (FACS) (Bold et al, 1999a, b).
In brief, following treatment, the cells were collected by gentle
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trypsinisation, washed in phosphate-buffered saline (PBS), and
pelleted by centrifugation. The cells were fixed in 70% ethanol,
washed twice in PBS and resuspended in PBS containing RNAse A
(20mg ml1). The cells were stained with PI (final concentration
0.1 mg ml1) for 10 min at room temperature. The samples
underwent FACS analysis (FL-3 channel) using a Beckman Coulter
Counter Epics XL flow cytometer (Beckman Coulter, Inc., Miami,
FL, USA). For each sample, 10 000 events were collected and stored
for subsequent analysis using EXPO software (version 2.0; Applied
Cytometry Systems, South Yorkshire, UK). Data were elaborated
using Autofit feature of the Multicycle for Windows software
(version 3.0, University of Washington, WA, USA) and expressed
as fraction of cells in the different cycle phases. The percentage of
cells in the sub-G0 phase was quantitated as an estimate of cells
undergoing apoptosis.
RESULTS
We confirmed that the MIA-PaCa-2 cell line demonstrates the
activation of AKT under basal conditions by Western blotting with
a phospho-specific (serine 473) antibody (Figure 1). The level of
AKT activation in MIA-PaCa-2 is well below that of the human
prostate cancer cell line LNCaP, which harbours a PTEN mutation
and thus has high levels of PI3K activity (Davies et al, 1999). In
comparison to MIA-PaCa-2, the pancreatic cancer cell line PANC-1
has very low levels of basal activation of AKT (Figure 1). The effect
of PI3K/AKT inhibition on the levels of the BCL-2 gene family was
determined by transiently transfecting MIA-PaCa-2 cells with
dominant-negative mutants of either PI3K or AKT and performing
Western blots. Both PI3K and AKT inhibition decreased BCL-2
expression and increased BAX expression without effect on MCL-
1, BCL-XL or BAK (Figure 2).
To determine whether these changes were mediated by
alterations in gene transcription, we focused our investigation on
the BCL-2 gene. To eliminate any potential effect of sequential
transfections, we utilised the established pharmacologic inhibitor
of PI3K, LY294002. Following treatment with LY294002, a dose-
dependent reduction in BCL-2 promoter activity was observed
only in the MIA-PaCa-2 cell line, but not in the PANC-1 cell line
(Figure 3), which has a much lower level of basal AKT activation.
We examined similarly the transactivational function of NF-kB,
given its potential regulatory function of BCL-2 gene transcription.
A parallel reduction in NF-kB function was also observed following
PI3K inhibition with LY294002 in the MIA-PaCa-2 cell line
(Figure 3C).
This decrease in the content of an antiapoptotic protein (BCL-2)
with an increase in the level of a proapoptotic protein (BAX) is
a pattern consistent with a lower threshold for the induction of
apoptosis. We determined whether these cells would undergo
spontaneous apoptosis following PI3K inhibition alone. Using flow
cytometry, we observed little change in the induction of apoptosis
following treatment with a wide range of doses of LY294002
(Figure 4). These cells exhibit a low level of spontaneous apoptosis,
which was unchanged following treatment with any dose of
LY294002. Of note, these doses were sufficient to decrease
dramatically BCL-2 transcription as seen above, as well as protein
levels (data not shown).
Having shown that the inhibition of AKT activation by PI3K
reduces NF-kB activity, BCL-2 promoter activity and subsequent
protein expression, we next sought to more definitively establish
the link between NF-kB and BCL-2. To do this, a putative NF-kB
site within the BCL-2 promoter underwent site-directed mutagen-
esis in which two bases were mutated. BCL-2 promoter activity
reduced by 77% following site-directed mutation of the putative
NF-kB site (Figure 5). The effect of mutating this NF-kB site in
conjunction with PI3K inhibition on BCL-2 promoter activity was
also examined. No further decrease in BCL-2 promoter activity was
seen when PI3K inhibition was combined with mutation of the NF-
kB site (Figure 5). These data indicate that NF-kB is the dominant
transcription factor activated by PI3K in the regulation of BCL-2
promoter function, and that the site at 736 nt is the major NF-kB
site.
Final confirmation of the role of NF-kB as mediator of the effect
of PI3K on BCL-2 was achieved by EMSA. Using a radiolabelled
18-base oligonucleotide corresponding to the putative NF-kB
site in the BCL-2 promoter (736 nt), the typical pattern of p50/
p65 and p50/50 bands are observed (Figure 6, lane 2). These
bands were competed away by an excess of unlabelled NF-kB
Figure 1 Levels of phospho-AKT (serine-473) and actin in the two
human pancreatic cancer cell lines MIA-PaCa-2 and PANC-1, with the
human prostate cancer cell line LNCaP as a positive control, which
harbours a mutation in PTEN and thus demonstrates constitutive activation
of PI3K (Davies et al, 1999).
Figure 2 Effect of inhibition of PI3K or AKT (through transient
transfection of the dominant-negative mutants (‘dom neg’) of these
kinases) on BCL-2 family protein expression. Actin is shown for equivalency
of loading.
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oligonucleotide (lane 3), but not by either oligonucleotides
representing the mutant NF-kB sequence from the site-directed
mutagenesis (lane 4) or an AP-1 consensus oligonucleotide (lane
5). The identity of the transcriptional element was confirmed by
adding the antibody to the p50 subunit of NF-kB to demonstrate a
supershifted complex (lane 6). Finally, the effect of PI3K inhibition
on this NF-kB binding to the 736 nt site in the BCL-2 promoter
was examined by treating the cells with LY294004 for 5 h prior to
nuclear protein harvest. Of specific interest is the elimination of
the upper p50/p65 complex only, with accentuation of the lower
p50/p50 complex. This suggests that the NF-kB signalling mediated
by PI3K is primarily through p65 activity with little effect on p50
activity.
As we observed very little apoptosis associated with the various
treatments employed to inhibit PI3K or AKT, we subsequently
investigated the cellular response to the inhibition of this sig-
nalling pathway as well as to exposure to gemcitabine, a standard
chemotherapy for pancreatic cancer. Using FACS analysis, we
observed a small increase in the induction of apoptosis with
gemcitabine (Figure 7), consistent with the literature that report
little apoptotic effect of gemcitabine in these cells following short-
term treatment (Xu et al, 2001). PI3K or AKT inhibition using the
dominant-negative constructs induced apoptosis to a minor degree
(Figure 7). However, there was a significant increase when the cells
were treated with gemcitabine in the presence of PI3K or AKT
inhibition (Figure 7). Therefore, the addition of PI3K or AKT
inhibition converts gemcitabine into a potent apoptotic agent.
DISCUSSION
Inhibition of the PI3K/AKT pathway has repeatedly and consis-
tently been shown to sensitise pancreatic cancer cells in vitro and
Figure 3 Treatment with the PI3K inhibitor, LY294002 inhibited the
activation BCL-2 promoter in the MIA-PaCa-2 cell line in a dose-dependent
manner(A) but without effect in the PANC-1 cell line (B). Furthermore,
LY294002 inhibited NF-kB transcriptional activity in MIA-PaCa-2 cells (C).
Total lysate firefly luciferase was normalised to Renilla luciferase following
dual transfection.
Figure 4 FACS analysis following 24 h of treatment with the indicated
doses of the PI3K inhibitor, LY294002. Also shown is the relative
percentage of cells in the sub-G0 phase of cell distribution, which
corresponds to the fraction undergoing apoptosis. Data is graphed by
number of events on x-axis and logarithmic value of flourescent intensity on
y-axis.
Figure 5 Effect of mutation of the NF-kB site on BCL-2 promoter
activity was examined using a full-length BCL-2 promoter/luciferase
reporter containing a site-specific mutation (‘mut.’) compared to the
wild-type BCL-2 promoter (‘w.t.’) in the absence or presence of LY294002.
Total lysate RLUs were normalised for protein concentration of the cellular
lysate for equivalency of analysis.
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in vivo to the apoptotic effect of chemotherapy. The mechanism by
which AKT activation in these cancer cells confers chemoresis-
tance is unclear. AKT has been shown to have multiple targets,
including mediators of apoptosis (e.g. caspase-9 and BAD),
transcription factors (e.g. FKHD and CREB) and assorted kinases
(e.g. raf, GSK-3 and IKK). There has been extensive investigation
coupling AKT to IKK and subsequent NF-kB activation, which can
be a potent survival signal through transcription of various target
genes. However, which genes confer this effect is undergoing
further investigation.
The effect of modifying single members of the BCL-2 gene
family on apoptotic response has been examined in a variety of
cancer types and models. However, it is now accepted that while
the levels of a single member of the BCL-2 gene family can be
associated with apoptotic response, the overall balance of
proapoptotic to antiapoptotic proteins (such as the BCL-2 : BAX
ratio) sets the threshold for the induction of apoptosis in response
to an external stimulus (Mirjolet et al, 2000). This is likely related
to the function of these proteins through their ability to homo- and
heterodimerise. Homodimers of proapoptotic proteins are suffi-
cient for the induction of apoptosis; high levels of expression of
antiapoptotic BCL-2 family members saturate the proapoptotic
members and prevent the initiation of the apoptotic cascade
(Mikhailov et al, 2001). Cancer cells are chemoresistant by
virtue of an elevated threshold for the induction of apoptosis
(termed ‘apopstat’). Indeed, dysregulation of BCL-2 gene family
expression is common in most cancers, although the mechanisms
are unclear.
Unlike other genetic events associated with cancer, altered
expression of BCL-2 family members appears to occur at the level
of transcription. A review of the reported effect of PI3K inhibition
on BCL-2 family transcription reveals diverse functions that are
dependent on cell type. In the JYTF-1 haematopoietic progenitor
cell line, PI3K inhibition decreased MCL-1 levels, but had no
effect on BCL-2 or BAX levels (Huang et al, 2000). On the other
hand, in FDCP-1 (B-cell progenitor line) or PC12 (rat pheochro-
mocytoma) cells, PI3K inhibition decreased BCL-2 gene transcrip-
tion (Minshall et al., 1999; Pugazhenthi et al, 2000). Finally, in
hippocampal neurons, PI3K inhibition decreased BCL-2 and
increased BAX (Matsuzaki et al, 1999). Our data show that PI3K/
AKT inhibition in these pancreatic cancer cells results in a
decrease in BCL-2 and an increase in BAX without effect on other
members of the BCL-2 family; furthermore, this effect appears
limited to those cell lines that demonstrate AKT activation under
basal conditions.
The specific mediators of BCL-2 transcription have been an
active area of research. Pugazhenthi reported that the PI3K-
mediated transcriptional regulation of BCL-2 was through
transactivation of the CREB transcription factor (Pugazhenthi
et al, 2000), although among the AKT-activated transcription
factors, NF-kB has been more consistently integrated into
antiapoptotic signalling through regulation of either BCL-XL or
A1/Bfl-1 (Wang W et al, 1999). Whether NF-kB functions as a
transcriptional activator or repressor of BCL-2 remains unclear.
Using the FL5.12 B-cell progenitor line, NF-kB activation repressed
transcription of the BCL-2 gene (Sohur et al. 1999). Conversely, in
a model of androgen withdrawal from prostate cancer cells, NF-kB
activation induced BCL-2 gene transcription (Catz and Johnson,
Figure 6 Examination of the NF-kB site at 736 nt within the BCL-2
promoter by EMSA. MIA-PaCa-2 nuclear lysate was incubated with
radiolabelled oligonucleotides corresponding to the NF-kB site (except
lane 1) and underwent cold competition (100 molar excess) of
nucleotides corresponding to the NF-kB site (lane 3), the site-directed
mutant of the NF-kB site (lane 4), or an unrelated transcriptional site, AP-1
(lane 5). Supershift of the NF-kB complex was achieved using an antibody
to the p50 subunit of NF-kB (lane 6). Treatment of the cells with
LY294002 eliminated the upper p50/p65 band of the typical NF-kB gelshift
pattern (lane 8).
Figure 7 FACS analysis following indicated treatments of LY294002
(10 mM), transient transfection with dominant-negative (DN) mutant forms
of either PI3K or AKT alone or in combination with gemcitabine (100 mM).
Also shown is the relative percentage of cells in the sub-G0 phase of cell
distribution, which corresponds to the fraction of cells undergoing
apoptosis. Data is displayed in similar format to that of Figure 4.
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2001). Heckman failed to identify a function NF-kB site in the
BCL-2 promoter of lymphoma cells harbouring a t(14:18)
translocation (Heckman et al, 2002), although the functional NF-
kB site we have identified is within the promoter analysed by these
investigators. It is clear from these various reports, that the
integrity and function of PI3K/NF-kB/BCL-2 signalling pathway is
dependent on a variety of factors, including cell type, genetic
background and transformed status. Of interest, we observed that
PI3K inhibition did not further decrease BCL-2 promoter activity
harbouring a mutated NF-kB site, suggesting that NF-kB alone was
the major transcription factor activated by PI3K, and it functioned
primarily at the 736 nt location.
Previous studies have demonstrated that the inhibition of PI3K
sensitises pancreatic cancer to the apoptotic effect of chemother-
apy; our studies provide data to define a signalling pathway that
involves alterations in relative levels of BCL-2 family members.
Inhibition of PI3K/AKT has minimal effect on the basal level of
apoptosis, although it leads to a lower threshold for the induction
of apoptosis in response to chemotherapy. These data suggest that
targeted inhibition of the PI3K/AKT pathway may not be an
appropriate therapy when administered alone, but may improve
the efficacy of standard chemotherapeutic agents. An improved
understanding of the mechanism(s) by which pancreatic cancer
cells evade apoptotic signals may result in the development of
novel therapies that can restore apoptotic sensitivity in this highly
lethal malignancy.
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